Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Shire Completes Combination With Baxalta Creating the Global Leader in Rare Diseases and Highly Specialized Conditions PR Newswire DUBLIN, June 3, 2016 DUBLIN, June 3, 2016 /PRNewswire/...
TransDigm Group Set to Join the S&P 500; Helen of Troy and Brocade Communications Systems to Join S&P MidCap 400; Team and MDC Holdings to Join S&P SmallCap 600 PR Newswire NEW YORK...
First paragraph, second sentence of release should read: Baxalta shareholders approved the definitive merger agreement with Shire, dated as of January 11, 2016, and the merger transaction...
Baxalta Incorporated (NYSE:BXLT) today announced the results of a vote on the proposals identified in the definitive proxy statement/prospectus, dated April 18, 2016, at a special meeting of...
OncoResponse, an immuno-oncology antibody discovery company, today announced an investment from Baxalta Incorporated (NYSE: BXLT). In October 2015, OncoResponse closed a Series A financing...
Single recombinant ADAMTS13 infusions demonstrated a favorable safety profile in adult and adolescent patients with severe hTTP hTTP is a rare blood clotting disease related to ADAMTS13...
First company established under Vitesse Biologics, an innovative collaboration formed by Baxalta, Mayo Clinic and Velocity Pharmaceutical Development Thunderbolt Pharma, Inc., will...
Baxalta Incorporated (NYSE:BXLT) today announced the preliminary results of the elections made by its stockholders as to the form of stock consideration to be received in Baxalta’s merger...
Merrimack and Baxalta Announce Initiation of Phase 1 Study of MM-151 in Combination with the ONIVYDE® (irinotecan liposome injection) Regimen in Metastatic Colorectal Cancer Study to evaluate...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
